Genkyotex (Euronext Paris & Brussels: FR00011790542 GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that the United States National Institutes of Health (NIH) has awarded an $8.9 million grant1 to Professor Victor Thannickal at the University of Alabama at Birmingham (UAB) to fund a multi-year research program evaluating the role of NOX enzymes in idiopathic pulmonary fibrosis (IPF), a chronic lung disease that results in fibrosis of the lungs. The core component of the program will be to conduct a 24-week Phase 2 trial of the Company’s lead product candidate, GKT831, in patients with IPF.

The trial will be fully funded via a grant from the United States National Institutes of Health to a consortium of leading academic institutions.

More information on :